These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32613802)

  • 21. Assessing the added value of health technologies: reconciling different perspectives.
    Drummond M; Tarricone R; Torbica A
    Value Health; 2013; 16(1 Suppl):S7-13. PubMed ID: 23317646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Co-Constitution of Health Systems and Innovation Comment on "What Health System Challenges Should Responsible Innovation in Health Address? Insights From an International Scoping Review".
    Peine A
    Int J Health Policy Manag; 2019 Nov; 8(11):665-667. PubMed ID: 31779292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.
    Mantovani LG; Cortesi PA; Strazzabosco M
    Hepatology; 2016 Oct; 64(4):1331-42. PubMed ID: 26926906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How can we assess the value of complex medical innovations in practice?
    Abrishami P; Boer A; Horstman K
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):369-71. PubMed ID: 25963313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis and innovation.
    Jena AB; Philipson TJ
    J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of research and value of development in early assessments of new medical technologies.
    Retèl VP; Grutters JP; van Harten WH; Joore MA
    Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine.
    de Windt TS; Sorel JC; Vonk LA; Kip MMA; Ijzerman MJ; Saris DBF
    J Tissue Eng Regen Med; 2017 Oct; 11(10):2950-2959. PubMed ID: 27401932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Researcher-driven versus policy-driven economic appraisal of health technologies: the case of France.
    Moatti JP; Chanut C; Benech JM
    Soc Sci Med; 1994 Jun; 38(12):1625-33. PubMed ID: 8047920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Health technology assessment: II. Cost effectiveness analysis].
    Secoli SR; Nita ME; Ono-Nita SK; Nobre M
    Arq Gastroenterol; 2010; 47(4):329-33. PubMed ID: 21225140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Decision modeling for economic evaluation of health technologies].
    de Soárez PC; Soares MO; Novaes HM
    Cien Saude Colet; 2014 Oct; 19(10):4209-22. PubMed ID: 25272129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Health Technologies: A UK Perspective Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".
    Parvizi N; Parvizi S
    Int J Health Policy Manag; 2017 Dec; 6(12):721-722. PubMed ID: 29172379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of probabilistic methods in economic evaluation of health technologies].
    Darbà J
    Gac Sanit; 2006; 20(1):74-7. PubMed ID: 16539999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
    Hartz S; John J
    Int J Technol Assess Health Care; 2008; 24(4):465-72. PubMed ID: 18828942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.